Developer docs
API playgroundTry for free, no card

Search company profiles

Bionique Testing Laboratories

Full company profile

uuid0008xob

Namestring
Bionique Testing Laboratories
Legal namestring
Bionique Testing Laboratories LLC
Websiteurl
bionique.com
Company typeenum
Private
Founded yearint
1990
Descriptiontext

Bionique Testing Laboratories LLC is a GMP FDA-registered contract research organization founded in 1990 and headquartered in Saranac Lake, New York, specializing exclusively in mycoplasma testing services for the biopharmaceutical industry. The company operates a single-site laboratory that recently completed a ~35,000 sq ft expansion (Grand Opening September 26, 2025) and is a wholly-owned subsidiary of Asahi Kasei Medical Co., Ltd. following a December 15, 2021 acquisition; it sits within Asahi Kasei Medical's Bioprocess Division alongside Austria-based sister company ViruSure GmbH.

The core technology portfolio combines classical compendial methods (Harmonized USP <63> / FDA Points to Consider / Ph. Eur. 2.6.7 / Japanese Pharmacopoeia) with a proprietary hybrid Real-Time PCR assay with broth enrichment (M-1500) that compresses 28-day compendial testing into 3-6 days while maintaining comparable sensitivity. The company also offers three proprietary mycoplasma media formulations, an automated DNA extraction workflow (AutoMate Express) that yields ~16% time savings and 45% throughput uplift, matrix qualification (M-1500Q), product-specific suitability studies (M-1550), and a broader assay development, validation, and transfer service line covering cell banks, raw materials, lot release, recombinant proteins, gene therapies, cell therapies, vaccines, and in vitro diagnostics.

Bionique generates revenue through professional services on a quote-based, pay-as-you-go contract testing model with optional expedited service tiers. The go-to-market is consultative B2B field sales combined with event-driven demand generation (Biotech Week Boston, Advanced Therapies Week, PDA Week, ASGCT, PDA Pharmaceutical Microbiology Conference) and content marketing. Customer base is concentrated in biopharmaceutical manufacturers, CDMOs, vaccine producers, and cell/gene therapy developers; recently named enterprise customers include Abeona Therapeutics, Cellipont Bioservices, and Bionova Scientific (a sister CDMO). Distribution is exclusively direct, with online sample submission forms and direct technical engagement by laboratory scientists.

Short descriptiontext

Bionique Testing Laboratories is a GMP FDA-registered contract research organization in Saranac Lake, NY, providing specialized mycoplasma testing services to biopharmaceutical manufacturers, CDMOs, and cell and gene therapy developers, operating as a subsidiary of Asahi Kasei Medical.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSaranac Lake, United States
HQ citystring
Saranac Lake
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
mycoplasma testing services, biosafety testing laboratory, cell bank testing, lot release testing, assay development validation
Industry3 codes
PRIMARYHLAAAKAG
Analytical Testing & QC Release Services (potency, purity, sterility)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLAFAMAD
Microbiology & Infectious Disease Testing Laboratories
NAICS code2 codes
  • Testing Laboratories and Services541380
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Testing Laboratories8734
  • Services-Commercial Physical & Biological Research8731
Product category
Mycoplasma Testing Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Mycoplasma Testing Services
TypeProfessional Services
Description

Bionique generates revenue through laboratory testing services including cell culture testing, raw materials testing, and lot release testing. Testing services follow GMP-compliant protocols and regulatory guidelines. Clients submit biological samples for mycoplasma detection using various methodologies including PCR and culture-based methods.

2Assay Development and Validation Services
TypeProfessional Services
Description

Contract services for developing and validating custom mycoplasma detection assays for client CMC purposes. Includes phase-appropriate validation, analytical method comparability studies, assay transfers, stability studies, custom study design, and regulatory consultancy.

bionique.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Others
Pricing details3 tiers
1Real-Time PCR Testing (M-1500)
ModelOtherBilling cadencePay-as-you-go
Notes

3-6 day turnaround, minimum 1.2 mL sample volume. Expedite services available at additional cost with E1, E2, E3 levels.

bionique.com
2Large Volume Barile Method (M-300)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

28-day testing, minimum 55 mL sample volume

bionique.com
3Large Volume Barile Method with DNA Fluorochrome (M-350)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

28-day testing, minimum 90 mL sample volume, 100 mL preferred

bionique.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Bionique Testing Laboratories is a GMP FDA-registered contract research organization that provides mycoplasma testing services for the biopharmaceutical and life science industry. Its core offering includes cell culture testing, raw materials testing, and lot release testing using culture-based methods, real-time PCR assays, and rapid microbial methods, complemented by assay development, validation, and regulatory consultancy for biologics, cell banks, vaccines, and cell and gene therapies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Time savings of approximately 1 hour (16%) per isolation with automated DNA extraction compared to manual methods
+2 more records
Product overview1 text field

Bionique Testing Laboratories offers a comprehensive portfolio of mycoplasma testing services for the biopharmaceutical industry, operating as a GMP FDA-registered contract research organization with 35+ years of experience. The core service offering includes compendial methods (Harmonized USP <63>, FDA Points to Consider, Ph. Eur. 2.6.7) and rapid molecular methods (Real-Time PCR with Broth Enrichment M-1500) for detection of mycoplasma contamination. Testing services span cell culture testing (M-150, M-250, M-700, M-1400, M-1500), raw materials testing (M-300, M-350), and lot release testing (M-1550), supported by assay development and validation services. The portfolio covers the full product lifecycle for biologics including cell banks, recombinant proteins, gene therapies, cell therapies, vaccines, and in vitro diagnostics. Bionique is a subsidiary of Asahi Kasei Medical's Bioprocess Division.

Product and service10 records
1Cell Culture Testing
CategoryCore Testing Service
Description

GMP-compliant mycoplasma testing for cell lines used in protein production, virus manufacturing, and cellular therapies, including Real-Time PCR with Broth Enrichment (M-1500), Matrix Qualification (M-1500Q), Harmonized USP <63> (M-1400), Inhibition Testing (M-1450), FDA Points to Consider (M-700), Multi-Media Direct Culture with DNA Fluorochrome (M-250), and DNA Fluorochrome Staining Assay (M-150). Targets biotech manufacturers using cell lines for therapeutic production.

2Raw Materials Testing
CategoryCore Testing Service
Description

Mycoplasma testing for sera, media, and other bioproducts to detect contamination in incoming raw materials, using the Large Volume Barile Method (M-300), Large Volume Barile Method with DNA Fluorochrome (M-350), and Harmonized USP <63> Test (M-1400). For raw material providers and biomanufacturers screening cell culture media, serum, supplements, and reagents.

3Lot Release Testing
CategoryCore Testing Service
Description

Quality control mycoplasma testing for final lot release of vaccines and biologics in accordance with global regulations, including Hybrid Real-Time PCR Phase Appropriate Suitability (M-1550), Inhibition Testing (M-1450), and Multi-Media Direct Culture (M-250). For biopharmaceutical companies producing biologics, biosimilars, and combination products.

4Assay Development, Validation Services and Transfer
CategoryCore Testing Service
Description

GMP-registered contract services for developing and validating custom mycoplasma detection assays, including Analytical Method Comparability Studies, Transfer of Assays, Stability Studies, Custom Study Design, and Regulatory Consultancy. Phase-appropriate per FDA, EMA, and ICH guidelines. For biopharmaceutical clients requiring CMC support and method validation.

5In Vitro Diagnostics Testing Support
CategoryTherapeutic Area Testing Service
Description

Mycoplasma testing services for in vitro diagnostics to ensure accuracy and freedom from mycoplasma contamination, supporting IVDs involving human cells, genetic testing, metabolic testing, and disease monitoring.

6Vaccines Testing Support
CategoryTherapeutic Area Testing Service
Description

Mycoplasma testing services for vaccine production, including live virus, inactivated virus, toxoid, conjugate, and mRNA vaccines, incorporated at multiple points in vaccine production workflow such as cell line seed stocks, cell line passaging, and receipt of new raw materials.

7Gene Therapies Testing Support
CategoryTherapeutic Area Testing Service
Description

Mycoplasma testing for gene therapy products, including in vivo and ex vivo delivery methods, supporting viral vectors (AAV), plasmid DNA, and patient-derived cellular gene therapies with rapid, small-volume testing assays.

8Cell Therapies Testing Support
CategoryTherapeutic Area Testing Service
Description

Mycoplasma testing for allogeneic, autologous, and multicellular cell therapies, including testing after every new passage and final material testing before patient re-infusion.

9Recombinant Proteins Testing Support
CategoryTherapeutic Area Testing Service
Description

Mycoplasma testing services for recombinant protein production, including monoclonal antibodies, divalent fusion proteins, enzymes, and scaffold proteins, supporting cell bank qualification and lot release.

10Cell Banks Testing Support
CategoryTherapeutic Area Testing Service
Description

Mycoplasma testing services for Master Cell Bank (MCB), Working Cell Bank (WCB), End of Production Cell Bank (EoPCB), and Research Cell Bank (RCB) qualification, supporting biotech manufacturers from research through GMP-compliant expansion.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-29
Description

Strategic partnership to advance the adoption and validation of rapid mycoplasma detection methods in support of cGMP manufacturing for cell and gene therapies. Bionique and Cellipont will collaborate to facilitate efficient manufacturing processes.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-20
Description

Bionova Scientific, a boutique commercial-scale biologics CDMO, appointed Bionique as the preferred provider for mycoplasma testing services. Both are subsidiaries of Asahi Kasei Corporation's medical division, strengthening the internal partnership network.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-09-16
Description

Collaboration to provide bioMérieux customers direct access to Bionique's product-specific validation services for the BIOFIRE FILMARRAY 2.0 Industry system for mycoplasma detection, facilitating efficient validation and implementation of the technology.

Strategic tierMajorTypeGTM or Marketing PartnerAnnounced on2021-01-26
Description

Bionique co-presented with ThermoFisher and American Pharmaceutical Review on Key Considerations for Implementing Rapid Microbial Methods for Mycoplasma Detection. ThermoFisher provides the MycoSEQ Real-Time PCR Detection Assay which Bionique has optimized for mycoplasma testing.

Strategic tierMinorTypeOthers
Description

ViruSure GmbH is another biosafety testing services company under Asahi Kasei Medical's Bioprocess Division. Both companies continue under their existing brands as part of the global biosafety testing services unit.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Sister company under Asahi Kasei Medical's Bioprocess Division, providing viral and prion safety testing services for biopharmaceuticals. Most direct comparable — both are specialized biosafety testing CROs under the same parent, serving overlapping biopharma clients.

TypeDirect peer
Description

Merck KGaA's biosafety testing services division, providing compendial and rapid microbiological testing (including mycoplasma) for biologics, vaccines, and cell/gene therapies. Directly competes for the same biopharma quality control testing engagements.

TypeBroad incumbent
Description

Large CRO offering comprehensive biopharmaceutical services including biosafety and mycoplasma testing within its broader manufacturing solutions and microbial testing portfolio. A well-established incumbent with much wider service breadth.

TypeBroad incumbent
Description

Global testing services network providing compendial mycoplasma testing, rapid methods, and biosafety testing for biopharmaceuticals. Operates as a broad incumbent offering testing within a wider contract laboratory portfolio.

TypeBroad incumbent
Description

Global testing, inspection, and certification company providing biosafety and microbiology testing services for biopharma. A broad incumbent offering mycoplasma and related testing within an extensive service portfolio.

TypeBroad incumbent
Description

Global CRO/CDMO providing comprehensive testing, manufacturing, and development services for biologics and cell/gene therapies, including biosafety testing. Broad incumbent with deep biopharma relationships, especially in cell and gene therapy.

TypeBroad incumbent
Description

Major clinical and bioanalytical laboratory offering biopharma testing services including biosafety and microbiology. Operates as a broad incumbent with extensive infrastructure across drug development.

TypeDirect peer
Description

Preclinical contract testing laboratory providing microbiology, biocompatibility, and analytical testing services for pharmaceutical, medical device, and biotech industries. Direct peer in specialized contract testing for regulated products.

TypeDirect peer
Description

Contract testing laboratory providing microbiology, analytical, and biosafety testing services for pharmaceutical and biotech clients. Direct peer in specialized microbiology testing for regulated industries.

TypeEmerging player
Description

Major bioprocess solutions provider with growing testing services portfolio for cell and gene therapy manufacturing. Emerging player in the rapid testing services space, with overlap in cell therapy and biosafety testing markets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bionique Testing Laboratories

Mycoplasma Testing Servicesbionique.com

Bionique Testing Laboratories is a GMP FDA-registered contract research organization in Saranac Lake, NY, providing specialized mycoplasma testing services to biopharmaceutical manufacturers, CDMOs, and cell and gene therapy developers, operating as a subsidiary of Asahi Kasei Medical.

What Bionique Testing Laboratories does

Bionique Testing Laboratories LLC is a GMP FDA-registered contract research organization founded in 1990 and headquartered in Saranac Lake, New York, specializing exclusively in mycoplasma testing services for the biopharmaceutical industry. The company operates a single-site laboratory that recently completed a ~35,000 sq ft expansion (Grand Opening September 26, 2025) and is a wholly-owned subsidiary of Asahi Kasei Medical Co., Ltd. following a December 15, 2021 acquisition; it sits within Asahi Kasei Medical's Bioprocess Division alongside Austria-based sister company ViruSure GmbH.

The core technology portfolio combines classical compendial methods (Harmonized USP <63> / FDA Points to Consider / Ph. Eur. 2.6.7 / Japanese Pharmacopoeia) with a proprietary hybrid Real-Time PCR assay with broth enrichment (M-1500) that compresses 28-day compendial testing into 3-6 days while maintaining comparable sensitivity. The company also offers three proprietary mycoplasma media formulations, an automated DNA extraction workflow (AutoMate Express) that yields ~16% time savings and 45% throughput uplift, matrix qualification (M-1500Q), product-specific suitability studies (M-1550), and a broader assay development, validation, and transfer service line covering cell banks, raw materials, lot release, recombinant proteins, gene therapies, cell therapies, vaccines, and in vitro diagnostics.

Bionique generates revenue through professional services on a quote-based, pay-as-you-go contract testing model with optional expedited service tiers. The go-to-market is consultative B2B field sales combined with event-driven demand generation (Biotech Week Boston, Advanced Therapies Week, PDA Week, ASGCT, PDA Pharmaceutical Microbiology Conference) and content marketing. Customer base is concentrated in biopharmaceutical manufacturers, CDMOs, vaccine producers, and cell/gene therapy developers; recently named enterprise customers include Abeona Therapeutics, Cellipont Bioservices, and Bionova Scientific (a sister CDMO). Distribution is exclusively direct, with online sample submission forms and direct technical engagement by laboratory scientists.

Bionique Testing Laboratories firmographics

Firmographics
Name
Bionique Testing Laboratories
Legal name
Bionique Testing Laboratories LLC
Website
https://bionique.com
Company type
Private
Founded year
1990
Operating status
Operating
Headcount range
11–50 employees
Short description
Bionique Testing Laboratories is a GMP FDA-registered contract research organization in Saranac Lake, NY, providing specialized mycoplasma testing services to biopharmaceutical manufacturers, CDMOs, and cell and gene therapy developers, operating as a subsidiary of Asahi Kasei Medical.
Ownership category
akta.pro rank

Bionique Testing Laboratories industry classification

Industry
Product category
Mycoplasma Testing Services
NAICS
Testing Laboratories and Services (541380), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAKAG
Analytical Testing & QC Release Services (potency, purity, sterility)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLAFAMAD
Microbiology & Infectious Disease Testing Laboratories

Keywords

  • Mycoplasma testing services
  • Biosafety testing laboratory
  • Cell bank testing
  • Lot release testing
  • Assay development validation

Where Bionique Testing Laboratories is headquartered

Location

Headquarters

HQ city
Saranac Lake
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Bionique Testing Laboratories business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Others

Revenue model

  1. Mycoplasma Testing Services: Bionique generates revenue through laboratory testing services including cell culture testing, raw materials testing, and lot release testing. Testing services follow GMP-compliant protocols and regulatory guidelines. Clients submit biological samples for mycoplasma detection using various methodologies including PCR and culture-based methods.
  2. Assay Development and Validation Services: Contract services for developing and validating custom mycoplasma detection assays for client CMC purposes. Includes phase-appropriate validation, analytical method comparability studies, assay transfers, stability studies, custom study design, and regulatory consultancy.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goReal-Time PCR Testing (M-1500)
Unit PricingPay-as-you-goLarge Volume Barile Method (M-300)
Unit PricingPay-as-you-goLarge Volume Barile Method with DNA Fluorochrome (M-350)

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Bionique Testing Laboratories product offering

Product offering

Core offering

Bionique Testing Laboratories is a GMP FDA-registered contract research organization that provides mycoplasma testing services for the biopharmaceutical and life science industry. Its core offering includes cell culture testing, raw materials testing, and lot release testing using culture-based methods, real-time PCR assays, and rapid microbial methods, complemented by assay development, validation, and regulatory consultancy for biologics, cell banks, vaccines, and cell and gene therapies.

Product overview

Bionique Testing Laboratories offers a comprehensive portfolio of mycoplasma testing services for the biopharmaceutical industry, operating as a GMP FDA-registered contract research organization with 35+ years of experience. The core service offering includes compendial methods (Harmonized USP <63>, FDA Points to Consider, Ph. Eur. 2.6.7) and rapid molecular methods (Real-Time PCR with Broth Enrichment M-1500) for detection of mycoplasma contamination. Testing services span cell culture testing (M-150, M-250, M-700, M-1400, M-1500), raw materials testing (M-300, M-350), and lot release testing (M-1550), supported by assay development and validation services. The portfolio covers the full product lifecycle for biologics including cell banks, recombinant proteins, gene therapies, cell therapies, vaccines, and in vitro diagnostics. Bionique is a subsidiary of Asahi Kasei Medical's Bioprocess Division.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cell Culture Testing GMP-compliant mycoplasma testing for cell lines used in protein production, virus manufacturing, and cellular therapies, including Real-Time PCR with Broth Enrichment (M-1500), Matrix Qualification (M-1500Q), Harmonized USP <63> (M-1400), Inhibition Testing (M-1450), FDA Points to Consider (M-700), Multi-Media Direct Culture with DNA Fluorochrome (M-250), and DNA Fluorochrome Staining Assay (M-150). Targets biotech manufacturers using cell lines for therapeutic production.
  • Raw Materials Testing Mycoplasma testing for sera, media, and other bioproducts to detect contamination in incoming raw materials, using the Large Volume Barile Method (M-300), Large Volume Barile Method with DNA Fluorochrome (M-350), and Harmonized USP <63> Test (M-1400). For raw material providers and biomanufacturers screening cell culture media, serum, supplements, and reagents.
  • Lot Release Testing Quality control mycoplasma testing for final lot release of vaccines and biologics in accordance with global regulations, including Hybrid Real-Time PCR Phase Appropriate Suitability (M-1550), Inhibition Testing (M-1450), and Multi-Media Direct Culture (M-250). For biopharmaceutical companies producing biologics, biosimilars, and combination products.
  • Assay Development, Validation Services and Transfer GMP-registered contract services for developing and validating custom mycoplasma detection assays, including Analytical Method Comparability Studies, Transfer of Assays, Stability Studies, Custom Study Design, and Regulatory Consultancy. Phase-appropriate per FDA, EMA, and ICH guidelines. For biopharmaceutical clients requiring CMC support and method validation.
  • In Vitro Diagnostics Testing Support Mycoplasma testing services for in vitro diagnostics to ensure accuracy and freedom from mycoplasma contamination, supporting IVDs involving human cells, genetic testing, metabolic testing, and disease monitoring.
  • Vaccines Testing Support Mycoplasma testing services for vaccine production, including live virus, inactivated virus, toxoid, conjugate, and mRNA vaccines, incorporated at multiple points in vaccine production workflow such as cell line seed stocks, cell line passaging, and receipt of new raw materials.
  • Gene Therapies Testing Support Mycoplasma testing for gene therapy products, including in vivo and ex vivo delivery methods, supporting viral vectors (AAV), plasmid DNA, and patient-derived cellular gene therapies with rapid, small-volume testing assays.
  • Cell Therapies Testing Support Mycoplasma testing for allogeneic, autologous, and multicellular cell therapies, including testing after every new passage and final material testing before patient re-infusion.
  • Recombinant Proteins Testing Support Mycoplasma testing services for recombinant protein production, including monoclonal antibodies, divalent fusion proteins, enzymes, and scaffold proteins, supporting cell bank qualification and lot release.
  • Cell Banks Testing Support Mycoplasma testing services for Master Cell Bank (MCB), Working Cell Bank (WCB), End of Production Cell Bank (EoPCB), and Research Cell Bank (RCB) qualification, supporting biotech manufacturers from research through GMP-compliant expansion.

Quantifiable outcome

  • Time savings of approximately 1 hour (16%) per isolation with automated DNA extraction compared to manual methods
  • +2 more outcomes

Companies that use Bionique Testing Laboratories

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Bionique Testing Laboratories technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Bionique Testing Laboratories partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core, major and minor.

  • Cellipont BioservicescoreStrategic or Co-development Partner · 29 May 2025Strategic partnership to advance the adoption and validation of rapid mycoplasma detection methods in support of cGMP manufacturing for cell and gene therapies. Bionique and Cellipont will collaborate to facilitate efficient manufacturing processes.
  • Bionova ScientificcoreStrategic or Co-development Partner · 20 March 2025Bionova Scientific, a boutique commercial-scale biologics CDMO, appointed Bionique as the preferred provider for mycoplasma testing services. Both are subsidiaries of Asahi Kasei Corporation's medical division, strengthening the internal partnership network.
  • bioMérieuxmajorStrategic or Co-development Partner · 16 September 2024Collaboration to provide bioMérieux customers direct access to Bionique's product-specific validation services for the BIOFIRE FILMARRAY 2.0 Industry system for mycoplasma detection, facilitating efficient validation and implementation of the technology.
  • ThermoFisher ScientificmajorGTM or Marketing Partner · 26 January 2021Bionique co-presented with ThermoFisher and American Pharmaceutical Review on Key Considerations for Implementing Rapid Microbial Methods for Mycoplasma Detection. ThermoFisher provides the MycoSEQ Real-Time PCR Detection Assay which Bionique has optimized for mycoplasma testing.
  • ViruSure GmbHminorOthersViruSure GmbH is another biosafety testing services company under Asahi Kasei Medical's Bioprocess Division. Both companies continue under their existing brands as part of the global biosafety testing services unit.

Scale indicators4 records

Recent moves8 records

Expansion highlights3 records

Bionique Testing Laboratories competitors and assessment

Company assessment

Direct peers

  • ViruSure GmbH: Sister company under Asahi Kasei Medical's Bioprocess Division, providing viral and prion safety testing services for biopharmaceuticals. Most direct comparable — both are specialized biosafety testing CROs under the same parent, serving overlapping biopharma clients.
  • BioReliance (Merck KGaA): Merck KGaA's biosafety testing services division, providing compendial and rapid microbiological testing (including mycoplasma) for biologics, vaccines, and cell/gene therapies. Directly competes for the same biopharma quality control testing engagements.
  • Toxikon Corporation: Preclinical contract testing laboratory providing microbiology, biocompatibility, and analytical testing services for pharmaceutical, medical device, and biotech industries. Direct peer in specialized contract testing for regulated products.
  • Pacific BioLabs (PacBio): Contract testing laboratory providing microbiology, analytical, and biosafety testing services for pharmaceutical and biotech clients. Direct peer in specialized microbiology testing for regulated industries.

Broad incumbents

  • Charles River Laboratories: Large CRO offering comprehensive biopharmaceutical services including biosafety and mycoplasma testing within its broader manufacturing solutions and microbial testing portfolio. A well-established incumbent with much wider service breadth.
  • Eurofins BioPharma Product Testing: Global testing services network providing compendial mycoplasma testing, rapid methods, and biosafety testing for biopharmaceuticals. Operates as a broad incumbent offering testing within a wider contract laboratory portfolio.
  • SGS Life Sciences: Global testing, inspection, and certification company providing biosafety and microbiology testing services for biopharma. A broad incumbent offering mycoplasma and related testing within an extensive service portfolio.
  • WuXi AppTec: Global CRO/CDMO providing comprehensive testing, manufacturing, and development services for biologics and cell/gene therapies, including biosafety testing. Broad incumbent with deep biopharma relationships, especially in cell and gene therapy.
  • Labcorp Drug Development: Major clinical and bioanalytical laboratory offering biopharma testing services including biosafety and microbiology. Operates as a broad incumbent with extensive infrastructure across drug development.

Emerging players

  • Sartorius AG: Major bioprocess solutions provider with growing testing services portfolio for cell and gene therapy manufacturing. Emerging player in the rapid testing services space, with overlap in cell therapy and biosafety testing markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Bionique Testing Laboratories social profiles

Digital presence

Bionique Testing Laboratories compliance and trust

Trust signal

Compliance1 record

Bionique Testing Laboratories financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bionique Testing Laboratories leadership team

Management profile

Number of profiles

Profiles5 records

Bionique Testing Laboratories funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bionique Testing Laboratories M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bionique Testing Laboratories

What does Bionique Testing Laboratories do?

Bionique Testing Laboratories is a GMP FDA-registered contract research organization that provides mycoplasma testing services for the biopharmaceutical and life science industry. Its core offering includes cell culture testing, raw materials testing, and lot release testing using culture-based methods, real-time PCR assays, and rapid microbial methods, complemented by assay development, validation, and regulatory consultancy for biologics, cell banks, vaccines, and cell and gene therapies.

Is Bionique Testing Laboratories a public or private company?

Bionique Testing Laboratories is a private company. It is classified as corporate owned and is currently operating.

When was Bionique Testing Laboratories founded?

Bionique Testing Laboratories was founded in 1990. It employs 11 to 50 people.

Where is Bionique Testing Laboratories based?

Bionique Testing Laboratories is headquartered in Saranac Lake, United States, in the North America region.

How does Bionique Testing Laboratories make money?

Two revenue lines are on record. Mycoplasma Testing Services are the primary driver. The others are assay Development and Validation Services.

Who are Bionique Testing Laboratories's main competitors?

Direct peers on record are ViruSure GmbH, BioReliance (Merck KGaA), Toxikon Corporation and Pacific BioLabs (PacBio). Broad incumbents are Charles River Laboratories, Eurofins BioPharma Product Testing, SGS Life Sciences, WuXi AppTec and Labcorp Drug Development. Sartorius AG is listed as an emerging player.

Does Bionique Testing Laboratories have an API?

No public API is recorded for Bionique Testing Laboratories.

What industry is Bionique Testing Laboratories in?

Bionique Testing Laboratories's product category is Mycoplasma Testing Services. Its primary akta.pro industry code is HLAAAKAG, Analytical Testing & QC Release Services (potency, purity, sterility), with a secondary code of HLAGADAH, Cell-Based & Potency Assays (Bioassays). Its NAICS code is 541380 and its SIC code is 8734.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireBionique Testing Laboratories Appoints Dr. Andy Bailey, Strengthening Global Biosafety TestingBionique Testing Laboratories, a subsidiary of Asahi Kasei, announced the appointment of Dr. Andy Bailey as President and Chief Executive Officer, effective April 1, 2026, with Dr. Bailey also assuming the role of Chief Scientific Officer at ViruSure to enable cross-company collaboration. The dual-role structure is designed to strengthen integration between Bionique and ViruSure, both part of Asahi Kasei's biosafety testing portfolio, following Bionique's recent expansion of approximately 35,000 square feet at its Saranac Lake, New York facility. Dr. Bailey brings over 30 years of experience in biological product safety, including founding ViruSure in 2005 and building it into a leading virus safety testing organization in Europe.PR NewswireBionique Testing Laboratories Strengthens Operations with ~35,000 Sq Ft Expansion to further support drug development and demand for rapid biosafety testing solutionsBionique Testing Laboratories has completed a major facility expansion of approximately 35,000 square feet at its Saranac Lake, New York location, more than tripling the size of its original 10,000 square foot facility to support drug development and biosafety testing demand. The expanded site includes purpose-built labs for mycoplasma, sterility, endotoxin, and viral testing, as well as flexible containment labs and BSL capabilities to serve biologics, cell and gene therapies, and advanced therapeutics. Bionique remains part of Asahi Kasei's Bioprocess division, with the expansion aligning to Asahi Kasei's strategy to invest in life science solutions with long-term growth potential.PR NewswireBionique Testing Laboratories and Cellipont Bioservices Partner to Accelerate Adoption of Rapid Mycoplasma Testing in Cell and Gene Therapy ManufacturingBionique Testing Laboratories and Cellipont Bioservices announced a strategic partnership on May 29, 2025, to advance the adoption and validation of rapid mycoplasma detection methods in cell and gene therapy manufacturing. The collaboration will enable Cellipont to integrate validated mycoplasma detection technologies into its quality control workflows, providing specialized testing services and product-specific validation support for regulatory alignment and accelerated batch release timelines. Both companies aim to address challenges in advanced therapy manufacturing including product complexity, limited batch yields, and the dynamic regulatory landscape.